Edwards Lifesciences (NYSE:EW) has earned FDA 510(k) clearance for Ecliptis, its left atrial appendage (LAA) exclusion system.
According to the FDA 510(k) database, the agency cleared the clip device on June 26. It marks the cardiac device giant’s entry. into the LAA device space, specifically pitting it against similar devices like AtriCure’s AtriClip and Medtronic’s Penditure system.
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang say limited details on the Ecliptis system’s design currently exist. They note that Edwards teased the device in early December 2025 at an Investor Day event. The FDA 510(k) database shows that Edwards submitted the device for clearance just weeks later on Dec. 29, 2025.
Additionally, the analysts say that Edwards indicated in February that it expected a preliminary commercial rollout later this year.
“We anticipate a measured, targeted rollout, with [Edwards] leveraging its established surgical valve infrastructure and relationships as the commercial foundation,” the analysts wrote.
Thibault, Eiber and Pang wrote that Ecliptis is positioned to compete directly with AtriClip and Penditure. They note that AtriCure already held off Medtronic’s Penditure to maintain its market share after concerns when Penditure first launched. Additionally, the analysts point out that AtriCure’s newer Flex-Mini device remains in the early stages of penetration.
“We expect ATRC shares could be weak today, but with this issue being the top concern among investors we spoke with, we think a product launch will serve as an eventual clearing event for ATRC shares, if the company can demonstrate limited share loss and continued strong growth for the AtriClip franchise,” the analysts said.
Currently, the market has plenty of devices targeting the LAA, including Abbott’s Amplatzer Amulet and the investigational Amulet 360, for which the company reported positive clinical findings last week.
The market also includes Boston Scientific’s Watchman system and the Conformal Medical/Gore CLAAS device.
